Free Trial

Beximco Pharmaceuticals (LON:BXP) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?

Beximco Pharmaceuticals logo with Medical background

Key Points

  • Beximco Pharmaceuticals (LON:BXP) has seen its stock price rise above the 50-day moving average, reaching a high of GBX 46.50 during trading.
  • The company's market capitalization is currently £202.76 million, with a P/E ratio of 3.19 and a beta of 0.61, indicating relatively low volatility.
  • Despite the recent uptick, Beximco Pharmaceuticals shares are down 2.3% as per the latest trading results.
  • MarketBeat previews the top five stocks to own by November 1st.

Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 43.57 ($0.59) and traded as high as GBX 46.50 ($0.63). Beximco Pharmaceuticals shares last traded at GBX 45.45 ($0.62), with a volume of 3,953 shares changing hands.

Beximco Pharmaceuticals Price Performance

The company has a quick ratio of 0.37, a current ratio of 2.13 and a debt-to-equity ratio of 12.47. The firm has a market cap of £211.46 million, a PE ratio of 3.33 and a beta of 0.61. The firm's fifty day simple moving average is GBX 44.21 and its two-hundred day simple moving average is GBX 39.76.

About Beximco Pharmaceuticals

(Get Free Report)

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.

Read More

Should You Invest $1,000 in Beximco Pharmaceuticals Right Now?

Before you consider Beximco Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beximco Pharmaceuticals wasn't on the list.

While Beximco Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.